$2.34
-0.02-0.85%
最終更新: Oct 8, 6:31 PM
$2.33
-0.03-1.27%
Benzinga
Benzinga
Benzinga
金曜日, 10 09
Benzinga
© 2026 Benzinga | All Rights Reserved
Ovid Therapeutics (OVID) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.10 | $-0.11 | $-0.10 | $-0.15 |
| Actual | $-0.08 | $-0.12 | $0.06 | $-0.17 |
| Surprise | +20.0% | -9.09% | +160.0% | -13.3% |
| Revenue | ||||
| Estimate | $30000 | $60664 | $133560 | $238228 |
| Actual | $733000 | $0 | $718000 | $132000 |
| Surprise | +2343.3% | -100.0% | +437.6% | -44.6% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.09 | $-0.09 | $-0.09 | $-0.09 |
| Revenue | ||||
| Consensus | $38872 | $151640 | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-0.08 | $-0.10 | 20.0 % |
| Q1 | May 12, 2026 | $-0.12 | $-0.11 | -9.09 % |
| Q4 | Mar 18, 2026 | $0.06 | $-0.10 | 160.0 % |
| Q3 | Nov 12, 2025 | $-0.17 | $-0.15 | -13.3 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $733.00K | $30.00K | 2343.3 % |
| Q1 | May 12, 2026 | $0 | $60.66K | -100.0 % |
| Q4 | Mar 18, 2026 | $718.00K | $133.56K | 437.6 % |
| Q3 | Nov 12, 2025 | $132.00K | $238.23K | -44.6 % |